Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 20/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 20/20 | 0.53 |
| ▸ | CDK2 | P24941 | 20/20 | 0.53 |
| ▸ | CDK9 | P50750 | 20/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2640001 | 0.90 | CCNT1 (0.49) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL2639350 | 0.90 | CCNT1 (0.49) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL2640115 | 0.86 | CCNT1 (0.54) | CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL2639320 | 0.84 | CCNT1 (0.54) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL2639358 | 0.82 | CCNT1 (0.50) | CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL2639792 | 0.81 | CCNT1 (0.51) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL2639967 | 0.80 | CCNT1 (0.48) | CCNT1CCNA2CDK2CDK9CCNA1 | |
| SCHEMBL2639639 | 0.79 | CCNT1 (0.49) | CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL13939892 | 0.77 | BRAF (0.38) | CCNT1CCNA2CDK2CDK9CDK5 | |
| SCHEMBL2639804 | 0.76 | BRAF (0.48) | CCNT1CCNA2CDK2CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4792126-B2 | — | — | 2011-10-12 | — | — | JP | claimed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | claimed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | claimed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | claimed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | CCNT1 1171/4885CCNA2 1821/4885CDK2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.